Clinical trials: Epithelial Tumor, Malignant
Metastatic Cancer, Epithelial Tumor
First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector
To characterise the safety and tolerability of NG-641 in patients with metastatic or advanced epithelial tumours.
- Trial name
- STAR (NCT04053283)
- Testing
- NG-641
- Where
- 6 sites in United States
- Volunteers
- 186 people
- Sponsor
- Akamis Bio
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are undergoing evaluation for or waitlisted for liver transplantation will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus…
- Trial name
- NCT05185505
- Testing
- Atezolizumab, Bevacizumab
- Where
- 2 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- The Methodist Hospital Research Institute
Small Cell Lung Cancer
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT04830813
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Pancreas Cancer, Non-Resectable Pancreas Carcinoma
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable pancreatic cancer, who are unfit for full-dose combination…
- Trial name
- NCT05841420
- Testing
- Gemcitabine, Nab paclitaxel
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Morten Ladekarl
Endometrial Cancer
Endometrial Cancer International Database
This project aims to determining prognostic factors and individualizing management decision per patient characteristics and endometrial cancer features.
- Trial name
- ECID (NCT04787159)
- Volunteers
- 1,000 people
- Sponsor
- Assiut University
HCC - Hepatocellular Carcinoma
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
The purpose of this study is to learn how well a combination of iparomlimab and tuvonralimab (QL1706), lenvatinib, radiotherapy, and hepatic arterial infusion chemotherapy (HAIC) works and how safe it is for people with…
- Trial name
- NCT07776080
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
ABC-108 is a single-arm Phase IIA clinical study of ABC294640 (Yeliva ®, opaganib) alone and in combination with hydroxychloroquine sulfate (HCQ) in the treatment of cholangiocarcinoma (CCA).
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT03377179
- Testing
- ABC294640, Hydroxychloroquine Sulfate 200 MG
- Where
- 5 sites in United States
- Volunteers
- 65 people
- Sponsor
- RedHill Biopharma Limited
Anaplastic Thyroid Cancer
interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)
Anaplastic thyroid cancer has historically proven very difficult to research due to a combination of its rarity and the associated short survival period for those affected.
- Trial name
- iNATT (NCT01774279)
- Testing
- Tissue, blood and clinical data collection
- Where
- 15 sites in Ireland, United Kingdom
- Volunteers
- 350 people
- Sponsor
- Velindre NHS Trust
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Hepatocellular Carcinoma(HCC), Cirrhotic Portal Hypertension
Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension
There is no consensus about the optimal treatment of hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, While this group of patients are classified as hepatectomy contraindication according to guidelines from…
- Trial name
- NCT01642446
- Testing
- Precise hepatectomy, Combined intervention (chemoembolization/ablation)
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Renal Cell Cancer, Neoplasm Metastasis
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
It is the aim of this clinical study to evaluate the skeletal-related event rate under therapy with zoledronic acid in patients with renal cell cancer having at least one cancer-related bone lesion.
- Trial name
- NCT00172003
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Vulvar Intraepithelial Neoplasia, HPV-Independent, Vulvar Squamous Cell Carcinoma
Evaluation of a Point-of-Care, AI-Powered Spectroscopy Device for Triage of Suspicious Vulvar Lesions: A Pilot Study
This purpose of this study is to assess the feasibility of using the DermaSensor™ device on vulvar skin.
- Conditions
- Vulvar Intraepithelial Neoplasia, HPV-Independent, Vulvar Squamous Cell Carcinoma, Vulvar Squamous Intraepithelial Lesion, HPV-Associated
- Trial name
- NCT07886203
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Laryngeal Squamous Cell Carcinoma
IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate
Laryngeal cancer is responsible for 2-5% of all new cancer cases worldwide. Squamous cell carcinoma of the larynx (LSCC) is the most common malignant tumor of the larynx, accounting for 85-90% of all laryngeal malignancies.
- Trial name
- IMP3PCNA (NCT05293327)
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Sohag University
Esophageal Squamous Cell Carcinoma
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma
This is a prospective single-arm study of endoscopic resection (ER) following concurrent chemoradiotherapy for stage I esophageal squamous cell carcinoma, to find if the treatment combination is useful by assessing its safety and…
- Trial name
- NCT04275986
- Testing
- Intensity modulated radiotherapy (IMRT), Chemotherapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Chinese Academy of Medical Sciences
Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer TNM Staging Primary Tumor (T) T1
Intravesical Adjuvant Electromotive Mitomycin-C
In laboratory and clinical studies, intravesical electromotive drug administration increased mitomycin bladder uptake, improving clinical efficacy in high-risk non-muscle invasive urothelial bladder cancer.
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) Ta, Bladder Cancer TNM Staging Primary Tumor (T) T1, Bladder Cancer Transitional Cell Grade
- Trial name
- EMDA/MMC (NCT01920269)
- Testing
- Trans-urethral resection, intravesical passive diffusion mitomycin, intravesical electromotive mitomycin
- Where
- Italy
- Volunteers
- 331 people
- Sponsor
- University of Rome Tor Vergata
Head and Neck Cancer
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00054054
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 95 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Melanoma, Non-small Sell Lung Cancer (NSCLC)
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v.
- Conditions
- Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer
- Trial name
- NCT02404441
- Testing
- PDR001
- Where
- 41 sites in United States, Canada and 12 more
- Volunteers
- 319 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
The goal of this clinical research study is to learn if the study drug SOM 230 in addition to standard therapy of gemcitabine can shrink or slow the growth of pancreatic cancer.
- Trial name
- NCT01385956
- Testing
- SOM 230 LAR, Gemcitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
NSCLC (Advanced Non-small Cell Lung Cancer)
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.
This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ALK201 for Injection combined with Ivonescimab Injection in adult patients with…
- Trial name
- NCT07742956
- Testing
- ALK201 for injection, Ivonescimab Injection
- Volunteers
- 156 people
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
This clinical trial studies the effect of standard verbal counseling with or without a pictorial educational tool for the reduction of psychological morbidity in patients with stage 0-IIIA breast cancer receiving radiation…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04993313
- Testing
- Counseling, Educational Intervention, Questionnaire
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- OHSU Knight Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.